SCH 56592 is a novel triazole antifungal agent that is active both orally a
nd intravenously. This compound is in phase II-m clinical trials for the tr
eatment of systemic fungal infections. A high-performance liquid chromatogr
aphic (HPLC) method was developed for the analysis of SCH 56592 in serum of
dogs, a species used for safety evaluation. The HPLC analysis involved pro
tein precipitation with methanol followed by separation on a C-18 column an
d quantitation by UV absorbance at 262 nm. The method was sensitive with a
limit of quantification of 0.05 mu g/ml in dog serum. The linearity was sat
isfactory as indicated by correlations of >0.996, in addition to visual exa
mination of the calibration curves. The precision and accuracy were satisfa
ctory as indicated by coefficients of variation (C.V;) ranging from 2.0 to
3.8%, and bias values ranging from -6.5 to 10%. Moreover, SCH 56592 was sta
ble in dog serum after being subjected to three freeze-thaw cycles. The ass
ay was shown to be sensitive, specific, accurate, precise, and reliable for
use in pharmacokinetic or toxicokinetic studies. (C) 2000 Elsevier Science
BN. All rights reserved.